Clinical Trial Update: Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy trial update for the TVGV-1 vaccine in HPV-induced cervical HSIL (high-grade cervical intraepithelial lesions).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia 3

Drugs mentioned

• TVGV-1 vaccine (TVGV-1)

Snippet

Sponsor: THEVAX Genetics Vaccine | Conditions: Human Papillomavirus, High-Grade Squamous Intraepithelial Lesions | Phase 2 | Status: UNKNOWN